These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 15566280)

  • 21. Optimize the interactions at S4 with efficient inhibitors targeting 3C proteinase from enterovirus 71.
    Zhang L; Huang G; Cai Q; Zhao C; Tang L; Ren H; Li P; Li N; Huang J; Chen X; Guan Y; You H; Chen S; Li J; Lin T
    J Mol Recognit; 2016 Nov; 29(11):520-527. PubMed ID: 27185390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diarylheptanoids from Alnus japonica inhibit papain-like protease of severe acute respiratory syndrome coronavirus.
    Park JY; Jeong HJ; Kim JH; Kim YM; Park SJ; Kim D; Park KH; Lee WS; Ryu YB
    Biol Pharm Bull; 2012; 35(11):2036-42. PubMed ID: 22971649
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of homology modeling of the severe acute respiratory syndrome (SARS) coronavirus main protease for structure based drug design.
    Takeda-Shitaka M; Nojima H; Takaya D; Kanou K; Iwadate M; Umeyama H
    Chem Pharm Bull (Tokyo); 2004 May; 52(5):643-5. PubMed ID: 15133227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural variations in keto-glutamines for improved inhibition against hepatitis A virus 3C proteinase.
    Jain RP; Vederas JC
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3655-8. PubMed ID: 15203137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Broad-spectrum inhibitors against 3C-like proteases of feline coronaviruses and feline caliciviruses.
    Kim Y; Shivanna V; Narayanan S; Prior AM; Weerasekara S; Hua DH; Kankanamalage AC; Groutas WC; Chang KO
    J Virol; 2015 May; 89(9):4942-50. PubMed ID: 25694593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heteroaromatic ester inhibitors of hepatitis A virus 3C proteinase: Evaluation of mode of action.
    Huitema C; Zhang J; Yin J; James MN; Vederas JC; Eltis LD
    Bioorg Med Chem; 2008 May; 16(10):5761-77. PubMed ID: 18407505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The substrate specificity of SARS coronavirus 3C-like proteinase.
    Fan K; Ma L; Han X; Liang H; Wei P; Liu Y; Lai L
    Biochem Biophys Res Commun; 2005 Apr; 329(3):934-40. PubMed ID: 15752746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis, biological evaluation and molecular modeling of a novel series of fused 1,2,3-triazoles as potential anti-coronavirus agents.
    Karypidou K; Ribone SR; Quevedo MA; Persoons L; Pannecouque C; Helsen C; Claessens F; Dehaen W
    Bioorg Med Chem Lett; 2018 Nov; 28(21):3472-3476. PubMed ID: 30286952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.
    Pillaiyar T; Manickam M; Namasivayam V; Hayashi Y; Jung SH
    J Med Chem; 2016 Jul; 59(14):6595-628. PubMed ID: 26878082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biosynthesis, purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C-like proteinase.
    Fan K; Wei P; Feng Q; Chen S; Huang C; Ma L; Lai B; Pei J; Liu Y; Chen J; Lai L
    J Biol Chem; 2004 Jan; 279(3):1637-42. PubMed ID: 14561748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-based design, synthesis, and evaluation of peptide-mimetic SARS 3CL protease inhibitors.
    Akaji K; Konno H; Mitsui H; Teruya K; Shimamoto Y; Hattori Y; Ozaki T; Kusunoki M; Sanjoh A
    J Med Chem; 2011 Dec; 54(23):7962-73. PubMed ID: 22014094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human coronavirus OC43 3CL protease and the potential of ML188 as a broad-spectrum lead compound: homology modelling and molecular dynamic studies.
    Berry M; Fielding B; Gamieldien J
    BMC Struct Biol; 2015 Apr; 15():8. PubMed ID: 25928480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-based design and synthesis of macrocyclic human rhinovirus 3C protease inhibitors.
    Namoto K; Sirockin F; Sellner H; Wiesmann C; Villard F; Moreau RJ; Valeur E; Paulding SC; Schleeger S; Schipp K; Loup J; Andrews L; Swale R; Robinson M; Farady CJ
    Bioorg Med Chem Lett; 2018 Mar; 28(5):906-909. PubMed ID: 29433930
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Invention of MK-7845, a SARS-CoV-2 3CL Protease Inhibitor Employing a Novel Difluorinated Glutamine Mimic.
    Shurtleff VW; Layton ME; Parish CA; Perkins JJ; Schreier JD; Wang Y; Adam GC; Alvarez N; Bahmanjah S; Bahnck-Teets CM; Boyce CW; Burlein C; Cabalu TD; Campbell BT; Carroll SS; Chang W; de Lera Ruiz M; Dolgov E; Fay JF; Fox NG; Goh SL; Hartingh TJ; Hurzy DM; Kelly MJ; Klein DJ; Klingler FM; Krishnamurthy H; Kudalkar S; Mayhood TW; McKenna PM; Murray EM; Nahas D; Nawrat CC; Park S; Qian D; Roecker AJ; Sharma V; Shipe WD; Su J; Taggart RV; Truong Q; Wu Y; Zhou X; Zhuang N; Perlin DS; Olsen DB; Howe JA; McCauley JA
    J Med Chem; 2024 Mar; 67(5):3935-3958. PubMed ID: 38365209
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic alpha,beta-unsaturated esters.
    Shie JJ; Fang JM; Kuo TH; Kuo CJ; Liang PH; Huang HJ; Wu YT; Jan JT; Cheng YS; Wong CH
    Bioorg Med Chem; 2005 Sep; 13(17):5240-52. PubMed ID: 15994085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SARS-CoV 3CL protease cleaves its C-terminal autoprocessing site by novel subsite cooperativity.
    Muramatsu T; Takemoto C; Kim YT; Wang H; Nishii W; Terada T; Shirouzu M; Yokoyama S
    Proc Natl Acad Sci U S A; 2016 Nov; 113(46):12997-13002. PubMed ID: 27799534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New Potent SARS-CoV 3C-Like Protease Inhibitors Derived from Thieno[2,3-d]-pyrimidine Derivatives.
    Abd El-All AS; Atta SM; Roaiah HM; Awad EM; Abdalla MM
    Arch Pharm (Weinheim); 2016 Mar; 349(3):202-10. PubMed ID: 26806115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, Synthesis, and Evaluation of Novel Prodrugs of Transition State Inhibitors of Norovirus 3CL Protease.
    Galasiti Kankanamalage AC; Kim Y; Rathnayake AD; Alliston KR; Butler MM; Cardinale SC; Bowlin TL; Groutas WC; Chang KO
    J Med Chem; 2017 Jul; 60(14):6239-6248. PubMed ID: 28671827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and testing of azaglutamine derivatives as inhibitors of hepatitis A virus (HAV) 3C proteinase.
    Huang Y; Malcolm BA; Vederas JC
    Bioorg Med Chem; 1999 Apr; 7(4):607-19. PubMed ID: 10353640
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stable benzotriazole esters as mechanism-based inactivators of the severe acute respiratory syndrome 3CL protease.
    Wu CY; King KY; Kuo CJ; Fang JM; Wu YT; Ho MY; Liao CL; Shie JJ; Liang PH; Wong CH
    Chem Biol; 2006 Mar; 13(3):261-8. PubMed ID: 16638531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.